Josephine van Dongen

4 Rotavirus vaccine effectiveness 111 Overall, there was little difference in results per pre-specified subgroup compared to the full cohor ts, but confidence intervals were wider because of smaller numbers. The estimated VE after at least one dose against severe rotavirus AGE varied between 3.3% for the subgroup of infants with a gestational age 30-32 weeks and 49.0% for subgroup of term infants with congenital disorders. See table S1 . Table S1 . Coefficients and hazard rates for subgroups Subgroup Coefficient * 95% CI Multivariate Hazard ratio * Gestational age 32-37 weeks -0.12 -2.08;0.37 0.89 Gestational age 30-32 weeks -0.03 -1.45;2.80 0.97 Gestational age below 30 weeks -0.26 -1.74;1.53 0.77 Term and congenital disorder -0.67 -3.30;5.50 0.51 Multiple risk conditions 0.25 -1.41;4.79 1.28 Rotavirus severe AGE as outcome comparing vaccinated versus unvaccinated infants in ATP cohor ts using the main analysis Cox model with an interaction term for subgroup. * Adjusted for daycare attendance and rotavirus epidemic intensity. Abbreviations: CI = confidence interval. All-cause AGE subgroup analyses With all-cause severe AGE as outcome in subgroup analyses, premature infants (GA 32-37 weeks) and term infants with a congenital disorder had a higher estimatedVE (44.6% and 68.0% respectively).And preterm infants of lowest gestational age (<30 weeks) or infants with multiple conditions seemed to benefit less from HRV vaccination (VE -3.6% and 4.4% respectively).